DOPAMINE AND
DOBUTAMINE
 Presented by :
Dr.Vishal kr.
Kandhway
INTRODUCTION
 Dopamine is an endogenous natural
catecholamine that serve as both a
neurotransmitter and a precursor of nor
epinephrine synthesis.
 When given as an exogenous drug dopamine
activates a variety of receptors in dose
dependent manner.
 Regulates cardiac, vascular and endocrine
function.
RECEPTORS
o Dopamine acts through D1 , D2 as well as
adrenergic alpha and B1 receptors ( But not B2)
o D1 and D2 receptors are the most abundant
and widespread in areas receiving a
dopaminergic innervation ( namely the
striatum ,limbic system, thalamus and
hypothalamus) as are D2 receptors, which also
occur in the pituitry gland
MECHANISM OF ACTION
 At dose of 0.5 to 3 mcg /kg /min :-
Selectively activates dopamine specific
receptors in the renal and splanchnic
circulation.
Increase blood flow in these region.
Low dose dopamine also directly affects
renal tubular epithelial cells.
It causes an increase in urinary Na
excretion
 At dose of 3 to 10 mcg /kg /min :-
It stimulates B1 receptors in the heart and peripheral
circulation.
Increases myocardial contractility, increases heart rate and peripheral
vasodilatation
It increases myocardial oxygen demand, so when ever dopamine is
to be used oxygen must be supplemented
Over all increase in cardiac output
Contractile response to dopamine is modest when compared
to dobutamine
 At dose of > 10 mcg /kg / min :-
Dopamine produces a progressive activation of alpha
receptors in the systemic and pulmonary circulation
resulting in progressive pulmonary and systemic
vasoconstriction
This vassopressor effect by virtue of increasing ventricular
afterload
Dopamine not effective orally and does not
cross blood brain barrier in sufficient amounts
to cause CNS effects.
PHARMACOKINETICS
 Rapid metabolism of dopamine mandates its
use as a continuous infusion. A portion of the
positive inotropic effect of dopamine is due
to stimulation of release of endogenous
norepinephrine which may predispose to
development of cardiac disarrythmias never
theless, dopamine is less disarrythmogenic
than epinephrine
 It is used only intravenously .
CLINICAL USES
 Dopamine is often used in situation where
both cardiac stimulation and peripheral
vasoconstriction desired such as cardiogenic
shock
 Also used to correct the hypotension in the
septic shock .But norepinephrine become the
preferred vassopressor in this condition
 Low dose is often used in an attempt to
prevent or reverse acute renal failure
 Drug initially administered at a rate of 2 to 5
mcg / kg /min . During infusion ,pt require
clinical assessments of myocardial function
perfusion of vitals organs such as the brain ,
and the production of urine
 Most pts should receive intensive care with
monitoring of arterial and venous pressures
and ECG
 Reduction in urine flow ,tachycardia or the
development of arrhythmias may be
indications to slow or terminate the infusion
DOPAMINE IN PULMONARY OEDEMA
 The sympathomimetic amines dopamine is
potent ionotropic agents
 Used in pulmonary edema
 Forcefully contracts the heart and thus
decreases the pulmonary load
DOPAMINE INFUSION IN WHICH
FLUID ?
 D-5–Yes
 RL -- No
 NS -- No
 DNS-- No
Conti-
 Low dose simultaneously increases:
Glomerular filtration rate
Renal blood flow
Urine output
DOSE AND ADMINISTRATION
 Commercial preparation of dopamine are
concentrated drug solution [Containing 40 mg
/80 mg dopamine HCL /ml]
 Provided in small volume vial / ampoule in 5 ml
/10 ml
 THE Preparation must be diluted to prevent
intense vasoconstriction during drug infusion
 Always delivered into , large central veins
DOSING REGIMEN
 There are two recommended doses:-
 3 to 10 mcg /kg /min is for augmenting
cardiac output thereby increasing BP
 More than 10 mcg /kg /min is
recommended to increase the blood pressure
directly
INCOMPABILITIES
 dopamine is inactivated by higher PH So ,
alkaline fluids should not be infused along
with dopamine
 INFUSATE:-
 Use 5 ml 2 vials containing 40 mg /ml
dopamine HCL add to 500 ml isotonic saline
PRECAUTIONS
 Before dopamine is administered to pt in
shock ,hypovolemia should be corrected by
transfusion of whole blood , plasma or other
appropriate fluid
ADVERSE EFFECTS
o Tachyarrhythmia's are the most common
adverse effects of dopamine
o Malignant tachyarrhythmia [ Multifocal
ventricular ectopic , ventricular tachycardia ]
o The most feared complication of dopamine
infusion is limb necrosis
o Extravasations of drug through a peripheral
vein can be treated with local injection of
phentolamine [5 to 10 mg in 15 ml saline ]
Contd…
 Allergic reactions
 Delays gastric emptying
 If pt is on dopamine infusion and is to be
anaesthetized , he / she will be treated as a
full stomach pt
 Less dysarrytmogenic than epinephrine
Contd…
 Continuous infusion of dopamine increase
intraocular pressure
 Ventilation effects :-
Infusion of dopamine interferes with the
ventilatory response to arterial hypoxemia
They results in unexpected depression of
ventilation
ABG have been observed to deteriote
during infusion of dopamine
Contd…
 Hyperglycemia that is commonly present in
pts receiving a continuous infusion of
dopamine is likely to reflect drug induced
inhibition of insulin secretion
CONTRAINDICATION
 Pt receiving MAO inhibitors
 Pheochromocytoma
 Uncorrected tachyarrhythmia
 Ventricular fibrillation
DOBUTAMINE
Name of drug;
 Dobutamine (generic name)
 Synthetic catecholamine derived from Isoproterenol.
Class of drug;
 Sympathomimetic
 Potent alfa 1 adrenergic agonist & weak B1-B2 adrenergic agonist.
 Vasopressor
PHARMACODYNAMIC PROPERTIES
 MECHANISM OF ACTION;
 Directly stimulates beta adrenergic receptor.
 Stimulation of Adenyl cyclase activity.
 Doesn‘t cause release of nor epinephrine.
 Cardiac Stimulation.
 Positive inotropic effect on myocardium.
 Increase in cardiac output by increase in stroke volume.
 Decrease in peripheral resistance.
 Increased myocardialOxygen consumption by increasing
tachycardia & myocardial contractility.
 Weak effects on vascular tone causing Peripheral
vasodilation.
 Increase in urine flow.
 Doesn‘t affect Dopaminergic receptor.
PHARMACOKINETICS
 Following IV administration
 Onset of action is 2 min
 Peak plasma conc. of drug is 10 min after initiation
of an IV infusion.
 Metabolism; ( in liver)
 Plasma half-life is 2 min
 Excretion mainly through urine.
 Dosage of adult and the elderly;
 2.5-10 mcg/kg/min
 Rarely upto 40mcg/kg/min may be
required.
INDICATIONS
 Inotropic support
 Cardiac failure
 Open heart surgery
 Positve end expiratory pressure
 Alternative to exercise in Cardiac stress
testing.
CONTRAINDICATIONS
 Hypersensitivity to dobutamine.
 Pheochromocytoma
 Must not be used in myocardial ischemia, in
case of ;
 Recent myocardial infarction,
 Unstable angina pectoris,
 Stenosis of main left coronary artery,
 Heart failure
Precautions ;
 Use with extreme caution after myocardial
ischemia
 Dose is decreased if there is undue increase in
heart rate, systolic blood pressue or arrythmia is
precipitated.
 Mild hypokalemia may occur.
 Sulphite sensitivity;
 Use with caution in sulphite – sensitive patients
because it causes allergy.
OVERDOSE
Symptoms;
 Anorexia
 Nausea, vomiting, tremor
 Headache, chest pain
 Excessive Hypertention
 Tachycardia
MANAGEMENT OF TOXICITY
 The initial action to be taken;
 Discontinuing administration of drug.
 Ensuring oxygenation and ventilation.
 If product is ingested , then absorption of drug
from GIT may be decreased by giving
activated charcoal. It is better than emesis
and gastric lavage.
ADVERSE DRUG REACTION
 Immune system disorders;
 Hypersensitivity reactions including;
 rash
 fever
 Anaphylactic reactions and severe life-
threatening asthmatic episodes may be due to
sulphite sensitivity.
DOPAMINE AND DOBUTAMINE
COMBINED INFUSION
 The divergent pharmacologic effects of
dopamine and dobutamine make their use in
combination potentially useful.Infusion of the
combination of dopamine and dobutamine
have been noted to produce a greater
improvement in cardiac output, at lower
doses, than can be achieved by either drug
alone.
 REFERENCES :
 Stoelting’s Pharmacology & Physiology.
 K.D.Tripathi Of Pharmacology.
Thank you…

Dopamine & dobutamine

  • 1.
    DOPAMINE AND DOBUTAMINE  Presentedby : Dr.Vishal kr. Kandhway
  • 2.
    INTRODUCTION  Dopamine isan endogenous natural catecholamine that serve as both a neurotransmitter and a precursor of nor epinephrine synthesis.  When given as an exogenous drug dopamine activates a variety of receptors in dose dependent manner.  Regulates cardiac, vascular and endocrine function.
  • 3.
    RECEPTORS o Dopamine actsthrough D1 , D2 as well as adrenergic alpha and B1 receptors ( But not B2) o D1 and D2 receptors are the most abundant and widespread in areas receiving a dopaminergic innervation ( namely the striatum ,limbic system, thalamus and hypothalamus) as are D2 receptors, which also occur in the pituitry gland
  • 4.
    MECHANISM OF ACTION At dose of 0.5 to 3 mcg /kg /min :- Selectively activates dopamine specific receptors in the renal and splanchnic circulation. Increase blood flow in these region. Low dose dopamine also directly affects renal tubular epithelial cells. It causes an increase in urinary Na excretion
  • 5.
     At doseof 3 to 10 mcg /kg /min :- It stimulates B1 receptors in the heart and peripheral circulation. Increases myocardial contractility, increases heart rate and peripheral vasodilatation It increases myocardial oxygen demand, so when ever dopamine is to be used oxygen must be supplemented Over all increase in cardiac output Contractile response to dopamine is modest when compared to dobutamine
  • 6.
     At doseof > 10 mcg /kg / min :- Dopamine produces a progressive activation of alpha receptors in the systemic and pulmonary circulation resulting in progressive pulmonary and systemic vasoconstriction This vassopressor effect by virtue of increasing ventricular afterload
  • 7.
    Dopamine not effectiveorally and does not cross blood brain barrier in sufficient amounts to cause CNS effects.
  • 8.
    PHARMACOKINETICS  Rapid metabolismof dopamine mandates its use as a continuous infusion. A portion of the positive inotropic effect of dopamine is due to stimulation of release of endogenous norepinephrine which may predispose to development of cardiac disarrythmias never theless, dopamine is less disarrythmogenic than epinephrine  It is used only intravenously .
  • 9.
    CLINICAL USES  Dopamineis often used in situation where both cardiac stimulation and peripheral vasoconstriction desired such as cardiogenic shock  Also used to correct the hypotension in the septic shock .But norepinephrine become the preferred vassopressor in this condition  Low dose is often used in an attempt to prevent or reverse acute renal failure
  • 10.
     Drug initiallyadministered at a rate of 2 to 5 mcg / kg /min . During infusion ,pt require clinical assessments of myocardial function perfusion of vitals organs such as the brain , and the production of urine  Most pts should receive intensive care with monitoring of arterial and venous pressures and ECG  Reduction in urine flow ,tachycardia or the development of arrhythmias may be indications to slow or terminate the infusion
  • 11.
    DOPAMINE IN PULMONARYOEDEMA  The sympathomimetic amines dopamine is potent ionotropic agents  Used in pulmonary edema  Forcefully contracts the heart and thus decreases the pulmonary load
  • 12.
    DOPAMINE INFUSION INWHICH FLUID ?  D-5–Yes  RL -- No  NS -- No  DNS-- No
  • 13.
    Conti-  Low dosesimultaneously increases: Glomerular filtration rate Renal blood flow Urine output
  • 14.
    DOSE AND ADMINISTRATION Commercial preparation of dopamine are concentrated drug solution [Containing 40 mg /80 mg dopamine HCL /ml]  Provided in small volume vial / ampoule in 5 ml /10 ml  THE Preparation must be diluted to prevent intense vasoconstriction during drug infusion  Always delivered into , large central veins
  • 15.
    DOSING REGIMEN  Thereare two recommended doses:-  3 to 10 mcg /kg /min is for augmenting cardiac output thereby increasing BP  More than 10 mcg /kg /min is recommended to increase the blood pressure directly
  • 16.
    INCOMPABILITIES  dopamine isinactivated by higher PH So , alkaline fluids should not be infused along with dopamine  INFUSATE:-  Use 5 ml 2 vials containing 40 mg /ml dopamine HCL add to 500 ml isotonic saline
  • 17.
    PRECAUTIONS  Before dopamineis administered to pt in shock ,hypovolemia should be corrected by transfusion of whole blood , plasma or other appropriate fluid
  • 18.
    ADVERSE EFFECTS o Tachyarrhythmia'sare the most common adverse effects of dopamine o Malignant tachyarrhythmia [ Multifocal ventricular ectopic , ventricular tachycardia ] o The most feared complication of dopamine infusion is limb necrosis o Extravasations of drug through a peripheral vein can be treated with local injection of phentolamine [5 to 10 mg in 15 ml saline ]
  • 19.
    Contd…  Allergic reactions Delays gastric emptying  If pt is on dopamine infusion and is to be anaesthetized , he / she will be treated as a full stomach pt  Less dysarrytmogenic than epinephrine
  • 20.
    Contd…  Continuous infusionof dopamine increase intraocular pressure  Ventilation effects :- Infusion of dopamine interferes with the ventilatory response to arterial hypoxemia They results in unexpected depression of ventilation ABG have been observed to deteriote during infusion of dopamine
  • 21.
    Contd…  Hyperglycemia thatis commonly present in pts receiving a continuous infusion of dopamine is likely to reflect drug induced inhibition of insulin secretion
  • 22.
    CONTRAINDICATION  Pt receivingMAO inhibitors  Pheochromocytoma  Uncorrected tachyarrhythmia  Ventricular fibrillation
  • 23.
    DOBUTAMINE Name of drug; Dobutamine (generic name)  Synthetic catecholamine derived from Isoproterenol. Class of drug;  Sympathomimetic  Potent alfa 1 adrenergic agonist & weak B1-B2 adrenergic agonist.  Vasopressor
  • 25.
    PHARMACODYNAMIC PROPERTIES  MECHANISMOF ACTION;  Directly stimulates beta adrenergic receptor.  Stimulation of Adenyl cyclase activity.  Doesn‘t cause release of nor epinephrine.  Cardiac Stimulation.
  • 26.
     Positive inotropiceffect on myocardium.  Increase in cardiac output by increase in stroke volume.  Decrease in peripheral resistance.  Increased myocardialOxygen consumption by increasing tachycardia & myocardial contractility.  Weak effects on vascular tone causing Peripheral vasodilation.  Increase in urine flow.  Doesn‘t affect Dopaminergic receptor.
  • 27.
    PHARMACOKINETICS  Following IVadministration  Onset of action is 2 min  Peak plasma conc. of drug is 10 min after initiation of an IV infusion.  Metabolism; ( in liver)  Plasma half-life is 2 min  Excretion mainly through urine.
  • 28.
     Dosage ofadult and the elderly;  2.5-10 mcg/kg/min  Rarely upto 40mcg/kg/min may be required.
  • 29.
    INDICATIONS  Inotropic support Cardiac failure  Open heart surgery  Positve end expiratory pressure  Alternative to exercise in Cardiac stress testing.
  • 30.
    CONTRAINDICATIONS  Hypersensitivity todobutamine.  Pheochromocytoma  Must not be used in myocardial ischemia, in case of ;  Recent myocardial infarction,  Unstable angina pectoris,  Stenosis of main left coronary artery,  Heart failure
  • 31.
    Precautions ;  Usewith extreme caution after myocardial ischemia  Dose is decreased if there is undue increase in heart rate, systolic blood pressue or arrythmia is precipitated.  Mild hypokalemia may occur.  Sulphite sensitivity;  Use with caution in sulphite – sensitive patients because it causes allergy.
  • 32.
    OVERDOSE Symptoms;  Anorexia  Nausea,vomiting, tremor  Headache, chest pain  Excessive Hypertention  Tachycardia
  • 33.
    MANAGEMENT OF TOXICITY The initial action to be taken;  Discontinuing administration of drug.  Ensuring oxygenation and ventilation.  If product is ingested , then absorption of drug from GIT may be decreased by giving activated charcoal. It is better than emesis and gastric lavage.
  • 34.
    ADVERSE DRUG REACTION Immune system disorders;  Hypersensitivity reactions including;  rash  fever  Anaphylactic reactions and severe life- threatening asthmatic episodes may be due to sulphite sensitivity.
  • 35.
    DOPAMINE AND DOBUTAMINE COMBINEDINFUSION  The divergent pharmacologic effects of dopamine and dobutamine make their use in combination potentially useful.Infusion of the combination of dopamine and dobutamine have been noted to produce a greater improvement in cardiac output, at lower doses, than can be achieved by either drug alone.
  • 36.
     REFERENCES : Stoelting’s Pharmacology & Physiology.  K.D.Tripathi Of Pharmacology.
  • 37.